Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

tralia. La reclutación de pacientes comenzó en junio de 2012. Los sujetos son pacientes con cáncer colorrectal no reseccionable, avanzado y recurrente que rechaza las quimioterapias estándares (fluoropirimidina, irinotecan, oxaliplatin, bevacizumab, y anticuerpo monoclonal EGFR en casos de tumor de tipo no mutado KRAS). El ensayo comparará a los pacientes aleatoriamente asignados para recibir TAS-102 o placebo para investigar la eficacia y seguridad de TAS-102. La medida de evaluación principal es la supervivencia general. Los principales investigadores son el doctor Atsushi Otsu , director del Clinical Development Center del National Cancer Center Hospital East (Japón), el doctor Robert J. Mayer del Dana Farber Cancer Institute (USA), y el doctor Eric Van Cutsem del University Hospital Gasthuisberg (Bélgica).

Acerca de Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, una filial de Otsuka Holdings Co., Ltd. (http://www.otsuka.com/en/), es una compañía farmacéutica de I+D centrada en los tres campos de oncología, alergias e inmunología, y urología. Su filosofía corporativa es una promesa: "Nos esforzamos por mejorar la salud humana y contribuir al enriquecimiento de la sociedad." En particular, en el campo de la oncología, Taiho Pharmaceutical es conocida como una compañía líder en Japón y en todo el mundo por el desarrollo de medicinas basadas en la evidencia para el tratamiento del cáncer. Además, en otras áreas distintas a la oncología, la compañía crea productos de calidad que tratan las enfermedades médicas de forma efectiva y pueden ayudar a mejorar la calidad de vida de las personas. Poniendo siempre al cliente en primer lugar, Taiho Pharmaceutical también pretende ofrecer productos médicos de
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... announced the results of the Company,s 2014 Annual General Meeting of ... , PRC. The required quorum, a majority of the common ... shareholders approved the following proposals:  , The re-election of ... Anderson , Kenneth Lee and Meng Mei ...
(Date:8/27/2014)...  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... be participating at the FBR Healthcare One on One ... Conference.  Details of the two events are as follows: ... Wednesday September 3 rd Location: Four Seasons, ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
... April 18, 2011 Qmed.com, a UBM Canon ... informative video clips of products and services available ... Vault . Qmed is a free online search ... access to pre-qualified medical device suppliers. ...
... 18, 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... March 31, 2011 on Wednesday, April 27, 2011, after the ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ...
Cached Medicine Technology:Qmed Video Vault Showcases Innovative New Products and Services Available to Medical Device Manufacturers 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:8/27/2014)... August 27, 2014 IQ Formulations ... today announced its continued support of the Cystic Fibrosis ... participated in a fundraising campaign led by TigerFitness.com in ... IQ Formulations’ sales were donated to the respected nonprofit ... a TigerFitness.com fundraiser to support Isla, a young girl ...
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first extensive ... O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... will be Buzz, a centralized surgical hub for operating ... navigation, imaging and communications connectivity. , Buzz Digital ... hardware all controlled from the full HD 42” multi-touch ...
(Date:8/27/2014)... 27, 2014 SCOTT Sports is ... Utah’s first indoor mountain bike and BMX park. SCOTT ... bikes in both adult and youth sizes for the park’s ... a distribution warehouse in Ogden, Utah, recently moved its U.S. ... “We are proud to be a partner with the Wasatch ...
(Date:8/27/2014)... By Steven Reinberg ... -- A hormone used to reduce the need for blood ... new study suggests. Synthetic erythropoietin (EPO), which stimulates red ... shortly after preterm birth, said lead researcher Dr. Petra Huppi, ... of Geneva, in Switzerland. "The real test of whether ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... For patients on hemodialysis, the use of dialysis filters ... approach to the common problem of anemia, reports a ... 39th Annual Meeting and Scientific Exposition in San Diego. ... Hospital in Vicenza, Italy, analyzed the outcomes of 172 ...
... acquired respiratory syndrome (SARS), has been responsible for around ... Researchers from Brookhaven’s biology department and the National Synchrotron ... controlling the virus . They have successfully identified a ... new anti-SARS virus drugs.The stage has been set now ...
... bypass surgery for morbid obesity have increased risk factors ... paper being presented at the American Society of Nephrology's ... ,'Gastric bypass surgery appears to lead to changes ... the formation of kidney stones,' comments Dr. Rajiv Kumar ...
... of clear information about the risks of nanotechnology in ... this powerful potential according //to 14 top international scientists ... issue of the journal Nature. The paper, 'Safe Handling ... nanotechnology risk that must be met if the technology ...
... China for stem cell treatment died on Thursday night in ... ,Willie Terpstra, a New Zealander, was diagnosed with motor ... months ago to have a foetal cell tansplantation operation in ... of voluntary muscle activity that aids speaking, breathing and swallowing. ...
Cached Medicine News:Health News:Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 3Health News:Gastric Bypass Surgery May Lead to Increased Kidney Stone Risk 2Health News:Fear of Possible Harm Hinder Nanotech Development 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The Invacare Pulse Oximeter provides fast, reliable SpO2 and pulse-rate measurements on any patient from infant to adult. It's designed for simple, accurate spot-checking and is a member of a full-li...
Rad-5v signal extraction pulse oximeter™...
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
Medicine Products: